Details of the Drug Reposition

General Information of This Drug (ID: DM7JNTV)

Drug Name
Halaven   DM7JNTV
Synonyms
Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Approved [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bladder cancer DISUHNM0 2C94 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2010
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)